CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 159 enrolled
Drug / intervention
IMA-638 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00425061
NCT00425061Phase 2Completed
CompareCT.gov

Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study Conducted Sequentially With 3 Doses Of Ima-638 Administered Sc.

Pfizer·interventional·Posted Jan 22, 2007·Updated Jan 14, 2015

In Brief

A Phase 2 clinical trial evaluating IMA-638 and placebo for Asthma. Completed, enrolled 159 participants across 82 sites in 2 countries.

Detailed Summary

Primary purpose is to assess if IMA-638 is safe and improves asthma in subjects with persistent asthma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 22, 2007
Enrollment StartFeb 1, 2007
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 19.4 years ago

Interventions

IMA-638biological

SC Injection, 12 weeks

IMA-638biological

SC Injection, 12 weeks

placeboother

placebo